Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,398.93
+0.8%
+61.82
Arrow-Thin-Down
DJI
49,609.16
+0.0%
+12.19
Arrow-Thin-Down
NASDAQ
26,247.08
+1.7%
+440.88
Arrow-Thin-Down
Bitcoin
$80,096.00
+0.0%
+$10.95
Arrow-Thin-Down
AAPL
$293.41
+2.1%
+$5.97
Arrow-Thin-Down
AMZN
$272.66
+0.5%
+$1.49
Arrow-Thin-Down
GOOG
$396.94
+0.4%
+$1.64
Arrow-Thin-Down
META
$609.53
-1.2%
-$7.28
Arrow-Thin-Down
MSFT
$415.17
-1.3%
-$5.60
Arrow-Thin-Down
NVDA
$215.16
+1.7%
+$3.66
Arrow-Thin-Down
TSLA
$427.99
+3.9%
+$16.20
Most Active StocksDaily Stock GainersDaily Stock Losers
Apellis Pharmaceuticals logo

Apellis Pharmaceuticals

(NASDAQ) APLS

Current Price$41.02
Market Cap$5.25B
Since IPO (2017)+192%
5 Year-13%
1 Year+128%
1 Month+1%

Apellis Pharmaceuticals Financials at a Glance

Market Cap

$5.25B

Revenue (TTM)

$1.03B

Net Income (TTM)

$133.27M

EPS (TTM)

$0.12

P/E Ratio

332.06

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$41.02

Volume

178,067

Open

$41.02

Previous Close

$41.02

Daily Range

$41.00 - $41.05

52-Week Range

$16.10 - $41.14

APLS News

A scientist looking through a microscope.

Best Biotech ETFs to Buy in 2026

Keith SpeightsApr 11, 2026
BuyAlert-Blue.png

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Jonathan PoncianoMar 21, 2026
Person checking medicine on a shelf in a pharmacy

Why Apellis Pharmaceuticals Wilted on Wednesday

Eric VolkmanMay 7, 2025
Person undergoing an eye exam

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

Eric VolkmanNov 5, 2024
a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

Cory RenauerOct 29, 2024
optometrist testing patients vision

Why Shares of Apellis Pharmaceuticals Were Down Wednesday

James HalleySep 27, 2023
downward trend

Why These 3 Nasdaq Stocks Buckled Today

George Budwell, PhDMay 16, 2023
doctor money

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

George Budwell, PhDMay 1, 2023
Page 1

APLS: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Apellis Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

739

CEO

Cedric Francois, MD, PhD

Website

www.apellis.com

Headquarters

Waltham, MA 02451, US

APLS Financials

Key Financial Metrics (TTM)

Gross Margin

89%

Operating Margin

16%

Net Income Margin

13%

Return on Equity

7%

Return on Capital

21%

Return on Assets

12%

Earnings Yield

0.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.25B

Shares Outstanding

128.02M

Volume

178.07K

Avg. Volume

4.97M

Financials (TTM)

Gross Profit

$901.55M

Operating Income

$55.43M

EBITDA

$70.00M

Operating Cash Flow

$45.33M

Capital Expenditure

$313.00K

Free Cash Flow

$45.01M

Cash & ST Invst.

$467.76M

Total Debt

$486.31M

Apellis Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$192.01M

+15.1%

Gross Profit

$151.46M

+14.4%

Gross Margin

78.88%

N/A

Market Cap

$5.25B

N/A

Market Cap/Employee

$7.45M

N/A

Employees

705

N/A

Net Income

$18.66M

+120.2%

EBITDA

$26.47M

+132.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$291.69M

+362.4%

Accounts Receivable

$440.30M

+80.2%

Inventory

$131.41M

+59.3%

Long Term Debt

$106.55M

-77.0%

Short Term Debt

$6.96M

+0.3%

Return on Assets

12.31%

N/A

Return on Invested Capital

20.68%

N/A

Free Cash Flow

$60.97M

-14.1%

Operating Cash Flow

$60.97M

-14.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SRRKScholar Rock Holding Corporation
$48.39+4.18%
CDTXCidara Therapeutics, Inc.
$221.38+0.00%
KNSAKiniksa Pharmaceuticals, Ltd.
$58.60+2.93%
CPRXCatalyst Pharmaceuticals, Inc.
$31.15-0.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$124.88+0.14%
RXTRackspace Technology
$5.49+0.56%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.37+0.06%
POETPoet Technologies
$10.88+0.14%

Questions About APLS

What is the current price of Apellis Pharmaceuticals?

Apellis Pharmaceuticals is trading at $41.02 per share.

What is the 52-week range for Apellis Pharmaceuticals?

Over the past 52 weeks, Apellis Pharmaceuticals has traded between $16.10 and $41.14.

How much debt does Apellis Pharmaceuticals have?

As of the most recent reporting period, Apellis Pharmaceuticals reported total debt of $475.76M.

How much cash does Apellis Pharmaceuticals have on hand?

Apellis Pharmaceuticals reported $406.73M in cash and cash equivalents in its most recent financial results.

What is Apellis Pharmaceuticals’s dividend yield?

Apellis Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services